Clinical Trial Update: Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM [Phase 1, Phase 2]

View source ↗

Summary

Tenaya Therapeutics announced a multi-center, open-label Phase 1/2 trial to evaluate safety and tolerability of TN-201 in adults with MYBPC3 mutation-associated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Drugs mentioned

• TN-201

Snippet

Sponsor: Tenaya Therapeutics | Conditions: Hypertrophic Cardiomyopathy | Phase 1, Phase 2 | Status: RECRUITING